Display options
Cite
Inoue K, Ninomiya J, Saito T, et al. Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):592-593doi: 10.1007/s10637-019-00773-9.
Inoue, K., Ninomiya, J., Saito, T., Okubo, K., Nakakuma, T., Yamada, H., Kimizuka, K., Higuchi, T. (2019). Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Investigational new drugs, 37(3), 592-593. https://doi.org/10.1007/s10637-019-00773-9
Inoue, Kenichi, et al. "Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial." Investigational new drugs vol. 37,3 (2019): 592-593. doi: https://doi.org/10.1007/s10637-019-00773-9
Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T. Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019 Jun;37(3):592-593. doi: 10.1007/s10637-019-00773-9. PMID: 31025237; PMCID: PMC6828019.
Copy Download .nbib Format: NLM
Share it on

Invest New Drugs. 2019 Jun;37(3):592-593. doi: 10.1007/s10637-019-00773-9.

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Investigational new drugs

Kenichi Inoue, Jun Ninomiya, Tsuyoshi Saito, Katsuhiko Okubo, Takashi Nakakuma, Hirofumi Yamada, Kei Kimizuka, Tohru Higuchi,

Affiliations

  1. Division of Breast Oncology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama, 362-0806, Japan. [email protected].
  2. Department of Breast Surgery, Ninomiya Hospital, Soka, Japan.
  3. Department of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan.
  4. Department of Breast Unit, Toda Central General Hospital, Saitama, Japan.
  5. Department of Breast Surgery, Ageo Central General Hospital, Ageo, Japan.
  6. Department of Surgery, Sekishindo Hospital, Saitama, Japan.
  7. Department of Breast Surgery, Kasukabe Medical Center, Kasukabe, Japan.

PMID: 31025237 PMCID: PMC6828019 DOI: 10.1007/s10637-019-00773-9

Abstract

The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.

Publication Types